According to research in the open-access journal, BMC Cancer, patients with hormone-negative cancer with bone metastases may benefit from bisphosphonate (BP) treatment. Of the 317 patients followed, 230 (72.6%) had hormone positive breast cancer and 87 patients (27.4%) had hormone negative.
Patients with hormone-positive breast cancer showed no benefit from BP. Those with hormone-negative, however, showed what researchers called “significant prolonged survival” from the drug. Disease-free survival was more than two years, with fewer than three metastatic sites. Patients received an average of 17.7 cycles of BP.
Download a PDF of the research here.